KR101519673B1 - 피레녹신을 함유하는 현탁형 수성 액제 - Google Patents

피레녹신을 함유하는 현탁형 수성 액제 Download PDF

Info

Publication number
KR101519673B1
KR101519673B1 KR1020097018762A KR20097018762A KR101519673B1 KR 101519673 B1 KR101519673 B1 KR 101519673B1 KR 1020097018762 A KR1020097018762 A KR 1020097018762A KR 20097018762 A KR20097018762 A KR 20097018762A KR 101519673 B1 KR101519673 B1 KR 101519673B1
Authority
KR
South Korea
Prior art keywords
container
pyrinoxine
castor oil
aqueous solution
trometamol
Prior art date
Application number
KR1020097018762A
Other languages
English (en)
Korean (ko)
Other versions
KR20090118960A (ko
Inventor
히로유키 아사다
세이지 요시다
나노코 츠티모토
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20090118960A publication Critical patent/KR20090118960A/ko
Application granted granted Critical
Publication of KR101519673B1 publication Critical patent/KR101519673B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
KR1020097018762A 2007-03-13 2008-03-13 피레녹신을 함유하는 현탁형 수성 액제 KR101519673B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2007-063787 2007-03-13
JP2007063787 2007-03-13
PCT/JP2008/054566 WO2008111630A1 (ja) 2007-03-13 2008-03-13 ピレノキシンを含有する懸濁型水性液剤

Publications (2)

Publication Number Publication Date
KR20090118960A KR20090118960A (ko) 2009-11-18
KR101519673B1 true KR101519673B1 (ko) 2015-05-12

Family

ID=39759561

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097018762A KR101519673B1 (ko) 2007-03-13 2008-03-13 피레녹신을 함유하는 현탁형 수성 액제

Country Status (5)

Country Link
JP (1) JP4958818B2 (zh)
KR (1) KR101519673B1 (zh)
CN (2) CN101636163B (zh)
TW (1) TWI465236B (zh)
WO (1) WO2008111630A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269575A1 (en) 2009-06-30 2011-01-05 Santen Pharmaceutical Co., Ltd Method for improving bioavailability of latanoprost

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021507A1 (en) * 2004-11-05 2007-01-25 Shirou Sawa Aqueous eye drops with accelerated intraocular migration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612537C1 (de) * 1986-04-14 1987-07-16 Dispersa Ag Arzneimittel zur Behandlung von Entzuendungen im Auge
DE3612538A1 (de) * 1986-04-14 1987-10-15 Dispersa Ag Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen
JPH0737386B2 (ja) * 1988-10-12 1995-04-26 参天製薬株式会社 懸濁型ピレノキシン点眼剤
JPH0676319B2 (ja) * 1988-12-20 1994-09-28 大正製薬株式会社 トコフェロール類含有液剤
JPH04300830A (ja) * 1991-03-28 1992-10-23 Zeria Pharmaceut Co Ltd ビタミンｅ類の水溶液の製剤
CN1101677C (zh) * 1997-05-30 2003-02-19 韩万愚 含有紫杉醇的药用注射溶液
WO2000059470A1 (fr) * 1999-04-05 2000-10-12 Senju Pharmaceutical Co., Ltd. Emulsion et son procede de production
JP4748289B2 (ja) * 2000-06-23 2011-08-17 ライオン株式会社 点眼剤、眼科用組成物及び吸着抑制方法
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
JP2005154437A (ja) * 2003-11-07 2005-06-16 Rohto Pharmaceut Co Ltd トラニラスト含有医薬組成物
CN100362991C (zh) * 2004-06-02 2008-01-23 刘继东 一种眼科用药物组合物
JP2006111621A (ja) * 2004-09-15 2006-04-27 Santen Pharmaceut Co Ltd ピレノキシン懸濁型点眼剤
WO2006030851A1 (ja) * 2004-09-15 2006-03-23 Santen Pharmaceutical Co., Ltd. ピレノキシン懸濁型点眼剤
JP2007008928A (ja) * 2005-06-01 2007-01-18 Rohto Pharmaceut Co Ltd アシタザノラスト含有水性組成物
JP2007119422A (ja) * 2005-10-31 2007-05-17 Santen Pharmaceut Co Ltd 合成樹脂成形物に吸着しやすい薬物の吸着抑制方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021507A1 (en) * 2004-11-05 2007-01-25 Shirou Sawa Aqueous eye drops with accelerated intraocular migration

Also Published As

Publication number Publication date
CN102716079A (zh) 2012-10-10
JP2008255111A (ja) 2008-10-23
CN102716079B (zh) 2015-07-08
JP4958818B2 (ja) 2012-06-20
TWI465236B (zh) 2014-12-21
TW200906415A (en) 2009-02-16
CN101636163A (zh) 2010-01-27
WO2008111630A1 (ja) 2008-09-18
KR20090118960A (ko) 2009-11-18
CN101636163B (zh) 2015-07-08

Similar Documents

Publication Publication Date Title
FI91217C (fi) Farmaseuttisen tai diagnostisen aineen oftalmologinen kantoainekoostumus
EP3096745B1 (en) Transdermal delivery system comprising donepezil or its salt
EP2506878A2 (en) Process for preparing pharmaceutical ophthalmic compositions
CA3174516A1 (en) Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
JPH01299230A (ja) ピロキシカムの医薬組成物水溶液およびその製造方法
KR101475965B1 (ko) 플루오로메토론을 함유하는 현탁형 점안제
EP2571488B2 (en) Pharmaceutical composition of ibuprofen for injection
KR101519673B1 (ko) 피레녹신을 함유하는 현탁형 수성 액제
EP2941437B1 (en) Polymorphic form c of trimacinolone acetonide
EP3370697B1 (en) Physically and chemically stable oral suspensions of givinostat
JPWO2018203424A1 (ja) 点眼剤
US10463674B2 (en) Process for manufacturing sterile ophthalmic pharmaceutical suspensions
WO2010119942A1 (ja) レボカバスチン懸濁型点眼剤
CN108136036A (zh) 包含瑞巴派特的新型眼科组合物及其制备方法
KR20230008148A (ko) 눈의 상황을 치료하기 위한 제제
JP2006111621A (ja) ピレノキシン懸濁型点眼剤
EP4316485A1 (en) Suspension containing heterocyclidene acetamide derivative
EP4082544A1 (en) Aqueous suspension composition containing sirolimus or salt thereof
WO2022195382A1 (en) A stable ophthalmic nanosupension of brinzolamide
Patel et al. Design and characterization of ofloxacin mucoadhesive in situ hydrogel
JP2005272461A (ja) 点眼剤
BENAVENT et al. YC-1 has been demonstrated to possess redundant biochemical mechanisms that confer significant stimulation upon NO-and CO-regulated, cyclase-dependent events. Menu
EP4240364A1 (en) Ophthalmic composition containing levofloxacin and ketorolac, method for the preparation and use thereof
WO2023148231A1 (en) Multidose ophthalmic compositions
CN116139249A (zh) 一种环孢素混悬滴眼液及其制备方法

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20180417

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20190417

Year of fee payment: 5